A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (NCT07284849)
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Who can join: Review the eligibility criteria below.
Location: Mitchell Cancer Institute — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (254 Sites)
Showing the first 25 of 254 sites.
- Mitchell Cancer Institute — Mobile, Alabama
- The University of Arizona Cancer Center — Tucson, Arizona
- Roche Tissue Diagnostics, Companion Diagnostics — Tucson, Arizona
- Memorial Care Orange Coast Medical Center — Fountain Valley, California
- Providence Medical Foundation — Fullerton, California
- Cancer & Blood Research Center — Los Alamitos, California
- University of California Los Angeles Health — Los Angeles, California
- Sarah Cannon Research Institute Scri Oncology Partners — Aurora, Colorado
- Hartford Hospital — Hartford, Connecticut
- George Washington University — Washington D.C., District of Columbia
- Florida Oncology & Hematology — Fort Myers, Florida
- University of Florida Health — Gainesville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Advent Health — Orlando, Florida
- Orlando Health Cancer Institute Downtown Orlando — Orlando, Florida
- Ascension Sacred Heart Pensacola — Pensacola, Florida
- Tampa General Hospital-Cancer Institute — Tampa, Florida
- Piedmont Cancer Institute — Locust Grove, Georgia
- University of Hawaii Cancer Center — Honolulu, Hawaii
- St Lukes Mountain States Tumor Institute Msti Boise — Boise, Idaho
- Sih Cancer Institute — Carterville, Illinois
- University of Illinois Cancer Center — Chicago, Illinois
- Endeavor Health — Evanston, Illinois
- Springfield Clinic — Springfield, Illinois
- Community Health Network, Inc. — Indianapolis, Indiana
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in CRC (Colorectal Cancer)
Explore by condition: All CRC (Colorectal Cancer) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.